Biohit Oyj (BIOBV.HE)
EUR 2.72
(-1.2%)
EUR 2.72
(-1.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.63 Million EUR | -63.22% |
| 2022 | 5.98 Million EUR | -19.33% |
| 2021 | 7.41 Million EUR | 3.95% |
| 2020 | 7.13 Million EUR | -11.7% |
| 2019 | 8.07 Million EUR | -3.87% |
| 2018 | 8.4 Million EUR | 15.65% |
| 2017 | 7.26 Million EUR | -1.44% |
| 2016 | 7.37 Million EUR | 9.1% |
| 2015 | 6.75 Million EUR | -2.69% |
| 2014 | 6.94 Million EUR | -8.75% |
| 2013 | 7.61 Million EUR | 43.21% |
| 2012 | 5.31 Million EUR | 138.17% |
| 2011 | -13.92 Million EUR | -144.43% |
| 2010 | 31.33 Million EUR | 14.25% |
| 2009 | 27.42 Million EUR | 2.3% |
| 2008 | 26.81 Million EUR | 1.06% |
| 2007 | 26.52 Million EUR | 5.56% |
| 2006 | 25.13 Million EUR | 9.21% |
| 2005 | 23.01 Million EUR | 10.24% |
| 2004 | 20.87 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.65 Million EUR | 10.0% |
| 2024 Q1 | 1.5 Million EUR | 36.36% |
| 2023 FY | 2.2 Million EUR | -63.22% |
| 2023 Q1 | 1.5 Million EUR | 50.0% |
| 2023 Q2 | 1.1 Million EUR | -26.67% |
| 2023 Q3 | 1.63 Million EUR | 48.59% |
| 2023 Q4 | 1.1 Million EUR | -32.7% |
| 2022 Q3 | 1.57 Million EUR | 74.67% |
| 2022 Q1 | 1.55 Million EUR | 40.91% |
| 2022 FY | 5.98 Million EUR | -19.33% |
| 2022 Q4 | 1 Million EUR | -36.39% |
| 2022 Q2 | 900 Thousand EUR | -41.94% |
| 2021 FY | 7.41 Million EUR | 3.95% |
| 2021 Q4 | 1.1 Million EUR | -39.23% |
| 2021 Q1 | 1.8 Million EUR | 157.14% |
| 2021 Q3 | 1.81 Million EUR | 81.0% |
| 2021 Q2 | 1 Million EUR | -44.44% |
| 2020 Q3 | 1.76 Million EUR | 60.0% |
| 2020 FY | 7.13 Million EUR | -11.7% |
| 2020 Q2 | 1.1 Million EUR | -40.54% |
| 2020 Q1 | 1.84 Million EUR | 32.14% |
| 2020 Q4 | 700 Thousand EUR | -60.23% |
| 2019 Q3 | 1.79 Million EUR | 19.43% |
| 2019 Q4 | 1.4 Million EUR | -21.85% |
| 2019 FY | 8.07 Million EUR | -3.87% |
| 2019 Q2 | 1.5 Million EUR | -30.23% |
| 2019 Q1 | 2.15 Million EUR | -3.61% |
| 2018 FY | 8.4 Million EUR | 15.65% |
| 2018 Q3 | 2.23 Million EUR | 11.53% |
| 2018 Q2 | 2 Million EUR | 0.0% |
| 2018 Q1 | 2 Million EUR | 1.83% |
| 2018 Q4 | 2.23 Million EUR | 0.0% |
| 2017 Q3 | 1.96 Million EUR | -16.43% |
| 2017 Q1 | 2.35 Million EUR | 7.43% |
| 2017 Q4 | 1.96 Million EUR | 0.0% |
| 2017 FY | 7.26 Million EUR | -1.44% |
| 2017 Q2 | 2.35 Million EUR | 0.0% |
| 2016 Q3 | 2.18 Million EUR | 4.17% |
| 2016 Q1 | 2.1 Million EUR | -17.87% |
| 2016 FY | 7.37 Million EUR | 9.1% |
| 2016 Q4 | 2.18 Million EUR | 0.0% |
| 2016 Q2 | 2.1 Million EUR | 0.0% |
| 2015 Q3 | 900 Thousand EUR | -47.06% |
| 2015 Q2 | 1.7 Million EUR | -5.56% |
| 2015 Q1 | 1.8 Million EUR | 3.21% |
| 2015 Q4 | 2.55 Million EUR | 184.11% |
| 2015 FY | 6.75 Million EUR | -2.69% |
| 2014 Q1 | 1.8 Million EUR | -5.76% |
| 2014 FY | 6.94 Million EUR | -8.75% |
| 2014 Q4 | 1.74 Million EUR | 9.0% |
| 2014 Q3 | 1.6 Million EUR | -11.11% |
| 2014 Q2 | 1.8 Million EUR | 0.0% |
| 2013 Q3 | 1.5 Million EUR | -46.43% |
| 2013 Q4 | 1.91 Million EUR | 27.33% |
| 2013 Q1 | 1.2 Million EUR | -8.68% |
| 2013 Q2 | 2.8 Million EUR | 133.33% |
| 2013 FY | 7.61 Million EUR | 43.21% |
| 2012 FY | 5.31 Million EUR | 138.17% |
| 2012 Q3 | 1.4 Million EUR | 0.0% |
| 2012 Q2 | 1.4 Million EUR | 7.69% |
| 2012 Q4 | 1.31 Million EUR | -6.14% |
| 2012 Q1 | 1.3 Million EUR | 103.57% |
| 2011 Q4 | -36.42 Million EUR | -627.87% |
| 2011 Q1 | 7.8 Million EUR | 148.88% |
| 2011 Q2 | 7.9 Million EUR | 1.28% |
| 2011 Q3 | 6.9 Million EUR | -12.66% |
| 2011 FY | -13.92 Million EUR | -144.43% |
| 2010 Q2 | 7.8 Million EUR | 6.85% |
| 2010 Q3 | 9.5 Million EUR | 21.79% |
| 2010 Q1 | 7.3 Million EUR | 167.69% |
| 2010 Q4 | 3.13 Million EUR | -67.01% |
| 2010 FY | 31.33 Million EUR | 14.25% |
| 2009 Q1 | 7 Million EUR | 0.0% |
| 2009 FY | 27.42 Million EUR | 2.3% |
| 2009 Q4 | 2.72 Million EUR | -65.04% |
| 2009 Q3 | 7.8 Million EUR | 14.71% |
| 2009 Q2 | 6.8 Million EUR | -2.86% |
| 2008 FY | 26.81 Million EUR | 1.06% |
| 2007 FY | 26.52 Million EUR | 5.56% |
| 2006 FY | 25.13 Million EUR | 9.21% |
| 2005 FY | 23.01 Million EUR | 10.24% |
| 2004 FY | 20.87 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Herantis Pharma Oyj | -154.36 Thousand EUR | 4400.762% |
| Nanoform Finland Oyj | 6.58 Million EUR | -0.758% |